奥赛康(002755) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥338,557,552.24, a decrease of 36.78% compared to ¥535,530,478.60 in the same period last year[18]. - The net profit for Q1 2023 was -¥75,383,018.82, representing a decline of 578.78% from a profit of ¥15,744,769.03 in the previous year[18]. - The total comprehensive income attributable to the parent company was -¥64,219,728.17, compared to ¥21,168,998.78 in the previous year[4]. - The total comprehensive income for the period was -¥69,360,660.14, contrasting with a positive figure of ¥17,869,761.02 in the previous year[4]. - Net profit attributable to shareholders of the listed company was -¥68,591,234.11, a decline of 454.23% from ¥19,363,474.87 in the previous year[28]. - Basic and diluted earnings per share were both -¥0.07, a decrease of 450.00% compared to ¥0.02 in the previous year[28]. Cash Flow - The net cash flow from operating activities was -¥110,779,210.22, a significant decrease of 665.11% compared to ¥19,603,258.69 in the same period last year[18]. - The net cash flow from operating activities was negative at -¥110,779,210.22, compared to a positive ¥19,603,258.69 in the previous period[40]. - Investment activities generated a net cash flow of ¥64,925,880.98, a significant improvement from a negative cash flow of -¥309,240,973.28 in the prior period[40]. - The cash outflow for operating activities totaled ¥514,876,351.57, compared to ¥668,515,802.93 in the previous period, showing a reduction of about 23.1%[40]. Expenses - Research and development expenses increased by 33.32% to ¥122,347,542.93, driven by ongoing investments in innovative and biological drug development[18]. - The company's sales expenses decreased by 36.84% to ¥214,979,509.61, reflecting the decline in revenue[18]. - Operating costs for the quarter were ¥66,056,085.50, compared to ¥62,513,029.96 in the previous year[24]. - The company reported a total operating cost of ¥431,430,413.60, down from ¥522,904,935.40 in the same period last year[24]. - The company experienced a significant increase in credit impairment losses, totaling ¥483,515.78 compared to ¥1,828,840.71 in the previous year[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,343,052,135.42, a decrease of 2.09% from ¥3,414,367,396.12 at the end of the previous year[28]. - The total liabilities amounted to ¥398,340,507.37, a slight decrease from ¥401,028,107.04 in the previous period, indicating a reduction of approximately 0.4%[36]. - Non-current liabilities totaled ¥87,558,087.12, up from ¥77,285,435.67, reflecting an increase of about 13.6%[36]. - The company's total equity was ¥2,944,711,628.05, a decrease from ¥3,013,339,289.08, reflecting a decline of approximately 2.3%[36]. Shareholder Information - The company had a total of 22,075 common shareholders at the end of the reporting period[19]. Inventory and Compensation - The company's inventory increased to ¥158,779,979.08 from ¥141,533,272.91, marking an increase of approximately 12.2%[43]. - The company reported a decrease in employee compensation payable to ¥15,450,807.12 from ¥41,419,835.05, a reduction of about 62.7%[43].